Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major cardiovascular events in diabetic patients were modest and not as robust as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback